AMENDMENT OF THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of claims in the application.

1. (Withdrawn) A method for inducing cell death in cancer cells, the method comprising treating cancer cells with an effective amount of TRAIL sufficient to induce apoptosis in at least a portion of the treated cancer cells.

2. (Withdrawn) A method for inducing cell death in cancer cells, the method comprising treating cancer cells with an effective amount of TRAIL and an effective amount of an antiprogestin sufficient to induce apoptosis in at least a portion of the treated cancer cells.

3. (Withdrawn) The method of claim 2, wherein the antiprogestin comprises Mifepristone.

4. (Withdrawn) A method for treating cancer by inducing cell death in cancer cells, the method comprising treating cancer cells with a pharmaceutical composition comprising an effective amount of TRAIL and an effective amount of Mifepristone sufficient to induce apoptosis in at least a portion of the treated cancer cells.

5. (Withdrawn) The method of claim 4, wherein the cancer cells are treated with Mifepristone prior to being treated with TRAIL.

6. (Withdrawn) The method of claim 4, wherein the cancer cells are treated with Mifepristone and TRAIL concurrently.

7. (Withdrawn) The method of claim 4, wherein the dose of TRAIL in said pharmaceutical composition results in a local concentration of TRAIL at the tumor which ranges from 1 to 1,000 ng/ml.

8. (Withdrawn) The method of claim 4, wherein the dose of TRAIL in said pharmaceutical composition results in a local concentration of TRAIL at the tumor which ranges from 200 to 600 ng/ml.

9. (Withdrawn) The method of claim 4, wherein the dose of TRAIL in said pharmaceutical composition results in a local concentration of TRAIL at the tumor which ranges from 350 to 450 ng/ml.

10. (Withdrawn) The method of claim 4, wherein the dose of Mifepristone in said pharmaceutical composition results in a local concentration of Mifepristone at the tumor which ranges from 1 to 1,000 μM.

11. (Withdrawn) The method of claim 4, wherein the dose of Mifepristone in said pharmaceutical composition results in a local concentration of Mifepristone at the tumor which ranges from 1 to 100 μM.

12. (Withdrawn) The method of claim 4, wherein the dose of Mifepristone in said pharmaceutical composition results in a local concentration of Mifepristone at the tumor which ranges from 5 to 20 μM.

13. (Withdrawn) The method of claim 4, wherein said cancer cells comprise prostate cancer cells.

14. (Withdrawn) The method of claim 13, wherein said prostate cancer cells comprise androgen responsive cells.

15. (Withdrawn) The method of claim 13, wherein said prostate cancer cells comprise cells which do not respond to androgen.

16. (Withdrawn) The method of claim 4, wherein the treatment of cancer cells with TRAIL and Mifepristone is associated with an increase in at least one death receptor in at least a portion of the treated cells.

17. (Withdrawn) The method of claim 16, further comprising an increase in the death receptor DR4 and/or DR5.

18. (Withdrawn) The method of claim 4, wherein the treatment of cancer cells with TRAIL and Mifepristone is associated with an increase in activated caspase enzymes.

19. (Withdrawn) The method of claim 18, wherein said activated caspases comprise caspase-8, caspase-7, caspase-9, or caspase-3.

20. (Withdrawn) The method of claim 4, wherein the treatment of cancer cells with TRAIL and Mifepristone is associated with an increase in truncated BID protein (tBid) in at least a portion of the treated cells.

21. (Withdrawn) The method of claim 4, wherein the treatment of cancer cells with TRAIL and Mifepristone is associated with a reduction in mitochondrial function.

22. (Withdrawn) The method of claim 4, wherein the treatment of cancer cells with TRAIL and Mifepristone results in an increase in apoptosome formation in at least a portion of the treated cells.

23. (Withdrawn) The method of claim 4, further comprising treating said cancer cells with a compound which reduces the concentration of active NFκB in said cells.

24. (Withdrawn) The method of claim 23, further comprising treating said cancer cells with IkB or an analogue thereof, wherein said analogue comprises a polypeptide which prevents activation of NFκB.

25. (Withdrawn) The method of claim 4, wherein the manner of treatment comprises intravenous injection of said pharmaceutical composition.

26. (Withdrawn) The method of claim 4, in combination with other means of treatment such as surgery, chemotherapy, or radiation therapy.

27. (Withdrawn) A composition for treating cancer by inducing cell death in cancer cells comprising an effective amount of TRAIL in a pharmaceutical carrier, wherein an effective amount comprises sufficient TRAIL to induce apoptosis in at least a portion of said cancer cells exposed to said composition.

28. (Currently amended) A composition for treating cancer by inducing cell death in cancer cells comprising an effective amount of a Tumor necrosis factor α - Related apoptosis Inducing Ligand (TRAIL) polypeptide comprising a wild-type TRAIL polypeptide having the amino acid sequence SEQ ID NO: 1, or the biological equivalent thereof, and an antiprogestin in a pharmaceutical carrier, wherein an effective amount comprises sufficient TRAIL polypeptide and antiprogestin to induce apoptosis in at least a portion of said cancer cells exposed to said composition.

29. (Original) The composition of claim 28, wherein the antiprogestin comprises Mifepristone.

30. (Currently amended) A composition for treating cancer by inducing cell death in cancer cells comprising an effective amount of a Tumor necrosis factor α - Related apoptosis Inducing Ligand (TRAIL) polypeptide comprising a wild-type TRAIL polypeptide having the amino acid sequence SEQ ID NO: 1, or the biological equivalent thereof, and Mifepristone in a pharmaceutical carrier, wherein an effective amount comprises sufficient TRAIL polypeptide and Mifepristone to induce apoptosis in at least a portion of said cancer cells exposed to said composition.

31. (Currently amended) The composition of claim 30, wherein said Mifepristone and said TRAIL polypeptide are packaged in such a manner that said Mifepristone is at least partially released for application to the cancer prior to the release of said TRAIL polypeptide.

32. (Currently amended) The composition of claim 30, wherein said Mifepristone and said TRAIL polypeptide are packaged in such a manner so as to be released substantially simultaneously.

33. (Currently amended) The composition of claim 30, wherein the dose of TRAIL polypeptide results in a local concentration of TRAIL polypeptide at the tumor which ranges from 1 to 1,000 ng/ml.

34. (Currently amended) The composition of claim 30, wherein the dose of TRAIL polypeptide results in a local concentration of TRAIL polypeptide at the tumor which ranges from 200 to 600 ng/ml.

35. (Currently amended) The composition of claim 30, wherein the dose of TRAIL polypeptide results in a local concentration of TRAIL polypeptide at the tumor which ranges from 350 to 450 ng/ml.

36. (Original) The composition of claim 30, wherein the dose of Mifepristone results in a local concentration of Mifepristone at the tumor which ranges from 1 to 1,000 μM.

37. (Original) The composition of claim 30, wherein the dose of Mifepristone results in a local concentration of Mifepristone at the tumor which ranges from 1 to 100 μM.

38. (Original) The composition of claim 30, wherein the dose of Mifepristone results in a local concentration of Mifepristone at the tumor which ranges from 5 to 20 μM.

39. (Original) The composition of claim 30, wherein said cancer cells comprise prostate cancer cells.

40. (Original) The composition of claim 39, wherein said prostate cancer cells comprise androgen responsive cells.

41. (Currently amended) The composition of claim 39, wherein said prostate cancer cells comprise cells ~~which~~ that do not respond to androgen.

42. (Currently amended) A kit for pharmaceutical treatment of cancer comprising:

(a) a pharmacologically effective amount of a Tumor necrosis factor α-Related apoptosis Inducing Ligand (TRAIL) polypeptide comprising a wild-type TRAIL polypeptide having the amino acid sequence SEQ ID NO: 1, or the biological equivalent thereof, packaged in a sterile container;

(b) a pharmacologically effective amount of an antiprogestin packaged in a sterile container;

(c) at least one aliquot of a pharmaceutical carrier; and

(d) instructions for application of said TRAIL polypeptide and said antiprogestin to a patient having cancer.

43. (Original) The kit of claim 42, wherein said antiprogestin comprises Mifepristone.

44. (Original) The kit of claim 42, wherein said cancer comprises prostate cancer.

45. (New) The composition of claim 28, wherein an effective amount of TRAIL polypeptide and antiprogestin results in an increase in at least one death receptor in at least a portion of the treated cells.

46. (New) The composition of claim 45, wherein the death receptor is at least one of DR4 or DR5.

47. (New) The composition of claim 28, wherein an effective amount of TRAIL polypeptide and antiprogestin results in an increase in activated caspase enzymes.

48. (New) The composition of claim 47, wherein said activated caspases comprise caspase-8, caspase-7, caspase-9, or caspase-3.

49. (New) The composition of claim 28, wherein an effective amount of TRAIL polypeptide and antiprogestin results in an increase in truncated BID protein (tBid) in at least a portion of the treated cells.

50. (New) The composition of claim 28, wherein an effective amount of TRAIL polypeptide and antiprogestin results in a reduction in mitochondrial function.

51. (New) The composition of claim 28, wherein an effective amount of TRAIL polypeptide and antiprogestin results in an increase in apoptosome formation in at least a portion of the treated cells.

52. (New) The composition of claim 28, wherein said antiprogestin and said TRAIL polypeptide are packaged in such a manner that said antiprogestin is at least partially released for application to the cancer prior to the release of said TRAIL polypeptide.